Condition
Lambert Eaton Myasthenic Syndrome (LEMS)
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Amifampridine
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Withdrawn1
Unknown1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07075627Withdrawn
A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)
NCT01378546UnknownPrimary
Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP
Showing all 2 trials
Research Network
Common Treatments
- Amifampridine1
Active Sponsors
- Addario Lung Cancer Medical Institute1
- Louis H. Weimer, MD1
Top Investigators
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Related Conditions
- Small Cell Lung Cancer Sclc1